Abstract: The invention relates to the use of mesenchymal stromal cells (MSCs) for treating sepsis in a subject. The invention provides compositions, uses and methods for the treatment of sepsis.
Type:
Application
Filed:
June 30, 2015
Publication date:
June 1, 2017
Applicant:
TiGenix S.A.U.
Inventors:
Wilfried DALEMANS, Eleuterio LOMBARDO, Robert DEKKER
Abstract: The present invention provides medical uses and methods for the intralymphatic administration of cellular therapies. Further aspects of the invention provide compositions, kits and uses for the intralymphatic administration of cellular therapies.
Abstract: The present invention provides methods for the intralymphatic administration of cellular therapies. Further aspects of the invention provide compositions, kits and uses thereof related to such methods.